167 related articles for article (PubMed ID: 37268012)
1. Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease.
Bernard JK; Marakovits C; Smith LG; Francis H
Semin Liver Dis; 2023 May; 43(2):226-233. PubMed ID: 37268012
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
3. Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma.
González MI; Vannan DT; Eksteen B; Flores-Sotelo I; Reyes JL
Cells; 2022 Jan; 11(3):. PubMed ID: 35159185
[TBL] [Abstract][Full Text] [Related]
4. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
6. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
[TBL] [Abstract][Full Text] [Related]
7. A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients.
Kruk B; Milkiewicz M; Raszeja-Wyszomirska J; Milkiewicz P; Krawczyk M
Orphanet J Rare Dis; 2022 Nov; 17(1):419. PubMed ID: 36397154
[TBL] [Abstract][Full Text] [Related]
8. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
Zhuang Y; Ortega-Ribera M; Thevkar Nagesh P; Joshi R; Huang H; Wang Y; Zivny A; Mehta J; Parikh SM; Szabo G
Hepatology; 2024 Apr; 79(4):752-767. PubMed ID: 37725754
[TBL] [Abstract][Full Text] [Related]
9. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
10. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
11. Keratin 7 expression in hepatic cholestatic diseases.
Sakellariou S; Michaelides C; Voulgaris T; Vlachogiannakos J; Manesis E; Tiniakos DG; Delladetsima I
Virchows Arch; 2021 Oct; 479(4):815-824. PubMed ID: 34312700
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
De Muynck K; Heyerick L; De Ponti FF; Vanderborght B; Meese T; Van Campenhout S; Baudonck L; Gijbels E; Rodrigues PM; Banales JM; Vesterhuus M; Folseraas T; Scott CL; Vinken M; Van der Linden M; Hoorens A; Van Dorpe J; Lefere S; Geerts A; Van Nieuwerburgh F; Verhelst X; Van Vlierberghe H; Devisscher L
Hepatology; 2024 Feb; 79(2):269-288. PubMed ID: 37535809
[TBL] [Abstract][Full Text] [Related]
13. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
14. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
15. The immunobiology of primary sclerosing cholangitis.
Aron JH; Bowlus CL
Semin Immunopathol; 2009 Sep; 31(3):383-97. PubMed ID: 19468733
[TBL] [Abstract][Full Text] [Related]
16. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.
Sarcognato S; Sacchi D; Grillo F; Cazzagon N; Fabris L; Cadamuro M; Cataldo I; Covelli C; Mangia A; Guido M
Pathologica; 2021 Jun; 113(3):170-184. PubMed ID: 34294935
[TBL] [Abstract][Full Text] [Related]
19. [Cholestatic liver diseases].
Grimm D; Thimme R
Ther Umsch; 2011 Apr; 68(4):195-9. PubMed ID: 21452140
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of biliary fibrosis.
Pinzani M; Luong TV
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1279-1283. PubMed ID: 28754450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
